An enhancer of Zeste homolog 2 (EZH2 in a cell or subject in need thereof by contacting a cell with a therapeutically effective amount of an EZH2 inhibitor or by administering to a subject a therapeutically effective amount of an EZH2 inhibitor (EZH2 ) Diseases characterized by abnormal activity, misregulation, or increased activity, such as immune evasion, cancer cell-induced immune dysfunction, reduced immune response, reduced inflammation, reduced expression of major histocompatibility complex (MHC). , Or providing a method of treating or alleviating the symptoms of cancer. A method of inhibiting immune evasion in a cancer cell comprising contacting said cell with a therapeutically effective amount of an EZH2 inhibitor. [Selection diagram] Fig. 9【課題】細胞を治療有効量のＥＺＨ２阻害剤に接触させることまたは被験体に治療有効量のＥＺＨ２阻害剤を投与することによる、それを必要とする細胞または被験体におけるＺｅｓｔｅホモログ２のエンハンサー（ＥＺＨ２）活性の異常、誤制御、または増大を特徴とする疾患、例えば、免疫回避、癌細胞誘導性免疫機能不全、免疫応答の減少、炎症の低下、主要組織適合遺伝子複合体（ＭＨＣ）の発現低下、または癌の症状を治療または緩和する方法の提供。【解決手段】癌細胞における免疫回避を阻害する方法であって、前記細胞を治療有効量のＥＺＨ２阻害剤と接触させるステップを含む方法。【選択図】図９
